News

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...
The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...
Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.
WASHINGTON-The Trump administration has embarked on a high-speed effort to negotiate ad hoc deals with more than 70 countries hoping to escape higher tariffs, with any agreements likely to fall short ...
As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.
While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.
Novo Nordisk A/S has a fifty-two week low of $60.61 and a fifty-two week high of $148.15. The company has a market capitalization of $285.03 billion, a price-to-earnings ratio of 19.31, a P/E/G ...
Novo Nordisk A/S Stock Performance Shares of NYSE NVO opened at $63.52 on Tuesday. The stock’s 50-day moving average is $80.37 and its 200 day moving average is $95.75. The stock has a market ...
Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais.
Global markets and businesses were thrown into disarray by U.S. President Donald Trump's tariff announcements on Thursday.